SCIENTIFIC LITERATURE · MED

[A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 2)--Report on clinical usefulness in diagnosis of degenerative neurological diseases and mental disorders].

Torizuka K, Uemura K, Toru M, Shinohara Y, Nishimura T, Yonekura Y, Nakagawara J, Matsuda H, Sakai F, Matsuda K, Fukuyama H, Morimoto K.

Kaku Igaku · 1996-03-01

PMID: 8622264

Check source for accessClinical Trial, Phase III; Clinical Trial; Multicenter Study; Journal ArticleOriginal source ↗

Research overview

This section identifies the original publication. Follow the source for its authors and journal.

Assess the question within the original study’s scope.

Check the source article for study design and sample details.

An editorially approved findings summary is not yet published for this record.

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.